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In this issue ofCancer Cell, Nickeleit et al. (2008) identify a new proteasome inhibitor, argyrin A, and show that
it induces apoptosis and inhibits angiogenesis via p27-dependent mechanisms. Their observations chal-
lenge current thinking about how this class of promising cancer therapies works and why they selectively
kill cancer cells.The proteasome is a multisubunit catalytic
complex consisting of three major enzy-
matic activities that is responsible for the
degradation of a large proportion of total
cellular proteins (Adams, 2004). Small-
molecule inhibitors of the proteasome
have been useful research tools for sev-
eral years, but recently they have gained
attention as cancer therapies with the US
Food and Drug Administration’s approval
of bortezomib (also known as PS-341 or
Velcade) for the treatment of multiple my-
eloma (MM) and mantle cell lymphoma.
Proteasome inhibition is also highly rele-
vant to the molecular mechanisms
involved in the tissue damage associated
with neurodegenerative disorders (Ben-
nett et al., 2007). Therefore, mechanistic
insights gained from studies of cancer
cells are potentially relevant to our under-
standing of the mechanisms involved in
neurodegeneration, and vice versa.
Some of the enthusiasm for developing
bortezomib as a therapy for cancer came
from work showing that the inflammation-
associated transcription factor NF-kB is
constitutively active in many different ad-
vanced cancers, coupled with the knowl-
edge that its physiological inhibitor (IkBa)
is regulated primarily at the level of the
proteasome (Adams, 2004) (Figure 1).
Subsequent studies have confirmed that
bortezomib and other proteasome inhibi-
tors block NF-kB, and recent work has
linked the clinical activity of the drug to
activating mutations in the NF-kB path-
way in patients with MM (Keats et al.,
2007). However, given the large number
of pathways that could potentially be
affected by proteasome inhibition, it
seemed unlikely that NF-kB inhibition
would account for all of bortezomib’s cy-
totoxic effects (Hideshima et al., 2002),
and more recently attention has turned
toward mechanisms that might be more
universally shared by cells when protea-
some function is blocked, including the
possible involvement of the ‘‘proteotoxic’’
stress that is caused by misfolded pro-
tein buildup. Several studies have shown
that bortezomib-induced apoptosis in
MM cells and other cancers is associated
with the activation of an endoplasmic
reticulum (ER) stress-response pathway
known as the unfolded protein response
(UPR) (Obeng et al., 2006), and apoptosis
in many models is mediated by caspase-
4, an ER-resident member of this family
of death proteases that is activated by
ER stress (Nawrocki et al., 2005). Further-
more, chemical and molecular inhibitors
of the coupling between the proteasome
and autophagy (the other major route of
intracellular protein degradation) can
synergize to promote apoptosis in cancer
cells.One suchapproach involvescombin-
ing proteasome inhibitors with inhibitors
of histone deacetylases, since the coupling
between the proteasome and autophagy
requires the cytosolic deacetylase HDAC6
(Nawrocki et al., 2006). Clinical trials have
opened to test the effects of proteasome
inhibitor and HDAC inhibitor combinations
in patients, and the preliminary results are
encouraging.
In their study, Nickeleit and colleagues
(2008) set up a high-throughput screen
to identify small molecules capable of
increasing the expression of p27kip1, a
polypeptide cyclin-dependent kinase
inhibitor, in cancer cells. Their screen
identifiedargyrinA,acyclic peptide derived
from the myxobacterium Archangium
gephyra. Functional studies revealed
that argyrin A is a potent inhibitor of the
proteasome’s three major enzymatic
activities and that all of the measured bio-
logical effects of the compound were de-
pendent on p27 but not on stabilization
of IkBa (Figure 1). Importantly, the investi-
gators found that bortezomib’s cytotoxic
effects were not p27 dependent, and
gene expression profiling suggested that
the effects of argyrin A were more similar
to the effects of proteasome subunit
knockdown than the effects of bortezomib
were. They concluded that argyrin A is a
‘‘purer’’ proteasome inhibitor than borte-
zomib and that bortezomib’s off-target
effects might explain why it kills cells via
a p27-independent mechanism. The ex-
pression profiling results confirmed that
bortezomib increases the expression of
genes associated with ER stress but that
argyrin A and proteasome subunit knock-
down do not.
This paper generates two conclusions
that are potentially paradigm shifting if
they can be confirmed. First, the general
explanation for why proteasome inhibi-
tors display selectivity for cancer cells is
that uncontrolled cell-cycle progression
makes these cells particularly vulnerable
to their effects (Drexler, 1997). In a more
general sense, the relationship between
cell-cycle progression and apoptosis has
been appreciated for over a decade as
a result of studies performed by Gerard
Evan, Doug Green, Scott Lowe, John
Cleveland, and others showing that Myc
and viral oncogenes that function like
Myc sensitize cells to apoptosis (Green
and Evan, 2002). Indeed, recent work
from M.S. Soengas’s group (Figure 1)
and our own observations have impli-
cated Myc in the proapoptotic effects of
bortezomib (Nikiforov et al., 2007), which
would seem to contradict the conclusion
that an inhibitor of cell-cycle progressionCancer Cell 14, July 2008 ª2008 Elsevier Inc. 1
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In this issue, Nickeleit and colleagues (2008) demonstrate that argyrin A is a novel proteasome inhibitor
and that it induces apoptosis and inhibits angiogenesis via p27-dependent mechanisms (left pathway).
On the other hand, studies with bortezomib or the structurally distinct inhibitor NPI-0052 (right pathways)
have implicated NF-kB inhibition, proteotoxic stress, and stabilization of Myc and downstream upregula-
tion of the BH3-only BCL-2 family member Noxa (among many other mechanisms) in cell death. The extent
to which proteasome inhibition versus off-target effects of each compound dictate their downstream ef-
fects in cancer cells requires further investigation. Clearly, these compounds have diverse effects on cells,
and attempting to identify final common pathways involved in their antitumor activities could be difficult.
However, the Nickeleit et al. study will cause a significant reevaluation of past results and could have
important implications for our understanding of how the proteasome might best be exploited in specific
cancers.like p27 would be centrally involved in the
cytotoxic effects of proteasome inhibi-
tors in cancer cells. Here, the potential off-
target effects of bortezomib or an extra-
nuclear cdk-independent mechanism of
p27 could explain the apparent discrep-
ancy. Several other structurally unrelated
proteasome inhibitors are now in clinical
development, and it will be interesting to
compare their on- and off-target effects
to bortezomib, argyrin A, and proteasome
subunit knockdown by expression profil-
ing and other approaches in future stud-
ies. One would imagine that they would
have very different off-target effects
that are not attributable to proteasome
inhibition.
The other striking conclusion is that the
effects of bortezomib on ER stress path-
way genes (Figure 1) may be related to
its off-target effects, since these effects
were not observed in cells exposed to ar-
gyrin A or siRNAs targeting proteasome
subunits. While this is conceivable, the
bulk of the available evidence here sug-
gests that protein aggregation probably
does play an important role. Perhaps the
best evidence supporting the aggregation
hypothesis has come from recent studies
of neurodegeneration, where elegant
work has established that the misfolded
proteins associated with disease cause
proteasome inhibition (Bennett et al.,
2007) and that the extent of protein
buildup dictates the extent of tissue dam-
age. Furthermore, studies in a Drosophila
eye model have directly demonstrated
that proteasome subunit knockdown in-
duces a stress that is caused by protein
aggregation (Pandey et al., 2007). Thus,
many investigators will remain attracted
to a model in which the protein aggrega-
tion caused by proteasome inhibition
plays a central role in cell death. It is cer-
tainly possible that p27 modulates these
effects, potentially by regulating autoph-
agy. One can imagine that protein aggre-
gation and features of ER stress could
occur without obvious changes in mRNA
expression as measured in microarrays.
Finally, the translational significance of
this work to proteasome inhibitor-based
therapies could be quite significant.
Even in disease sites like MM where it is
active, bortezomib induces major clinical
responses in a minority of patients
(<40%), and no patient has been cured
with the drug. Recent studies indicate2 Cancer Cell 14, July 2008 ª2008 Elsevier Inc.that structurally distinct proteasome in-
hibitors like NPI-0052 kill cells via mecha-
nisms that are distinct from those elicited
by bortezomib (Chauhan et al., 2005), and
based on these data, it seems clear that
argyrin A also works by a distinct mecha-
nism. Therefore, by combining these
agents or using them in different subsets
of tumors, we may be able to better attack
the intertumoral heterogeneity that limits
therapeutic efficacy in MM and other pro-
teasome inhibitor-sensitive cancers.
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